The Effect of Metformin in Patients With Metastatic Castration-resistant Prostate Cancer

Summary

The purpose of this study is to assess the effect of the addition of metformin to abiraterone on survival in patients with metastatic castration-resistant prostate cancer (mCRPC). The half the patients will receive metformin in combination with androgen deprivation therapy (ADT) and abiraterone, and the other half will receive ADT and abiraterone only.

Timeline

Start

2021-06-23

Primary completion

2024-04-30

Completion

2024-08-31

Drugs

Indications